Advertisement

Topics

"Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen" Drugs and Medication Database

22:12 EST 23rd January 2019 | BioPortfolio

Here are the most relevant "Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen" Drugs and Medications that we have found in our database.

More Information about "Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen" on BioPortfolio

We have published hundreds of Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen news stories on BioPortfolio along with dozens of Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen Clinical Trials and PubMed Articles about Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen Companies in our database. You can also find out about relevant Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen Drugs and Medications on this site too.

Showing "Ranibizumab Treatment Choroidal Neovascularisation Secondary Pathological Myopia Individualized" Drugs and Medications 1–25 of 38

Probably Relevant

Lucentis [Genentech, Inc.]

These highlights do not include all the information needed to use LUCENTIS safely and effectively. See full prescribing information for LUCENTIS. LUCENTIS (ranibizumab injection) for intravitreal injection Initial U.S. Approval: 2006

Eylea [Regeneron Pharmaceuticals, Inc.]

These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA (aflibercept) Injection, for Intravitreal InjectionInitial U.S. Approval: 2011

Possibly Relevant

Visudyne [QLT Ophthalmics, Inc.]

VISUDYNE (VERTEPORFIN FOR INJECTION)

Visudyne [Valeant Pharmaceuticals North America LLC]

These highlights do not include all the information needed to use VISUDYNE® safely and effectively. See full prescribing information for VISUDYNE®.VISUDYNE® (verteporfin for injection), for intravenous useInitial U.S. Approval: 2000

Ak-fluor [Akorn]

These highlights do not include all the information needed to use AK-FLUOR 10% and AK-FLUOR 25% safely and effectively. See full prescribing information for the products in AK-FLUOR 10% and AK-FLUOR 25%. AK-FLUOR (fluorescein injection, USP) 10% and AK-FL

Mitosol [Mobius Therapeutics LLC]

These highlights do not include all the information needed to use Mitosol safely and effectively. See full prescribing information for Mitosol. Mitosol (mitomycin for solution) for ophthalmic useInitial U.S. Approval: 1974

Fluorescite [Alcon Laboratories, Inc.]

These highlights do not include all the information needed to use FLUORESCITEsafely and effectively. See full prescribing information for FLUORESCITE (fluorescein injection, USP) 10%. FLUORESCITE (fluorescein injection, USP) 10% Intravenous injection Init

Indocyanine green [Novadaq Technologies Inc.]

Indocyanine Green for Injection USP

Indocyanine green [Novadaq Technologies Inc.]

Indocyanine Green for Injection USP

Indocyanine green [Novadaq Technologies Inc.]

Indocyanine Green for Injection USP

Ic-green [Novadaq Technologies Inc.]

IC‑GREEN™

Ic-green [Novadaq Technologies Inc.]

IC‑GREEN™

Ic-green [Novadaq Technologies, Inc.]

IC-GREEN™

Pantoprazole sodium [DirectRX]

PANTOPRAZOLE SODIUM

Retisert [Bausch & Lomb Incorporated]

These highlights do not include all the information needed to use RETISERT safely and effectively. See full prescribing information for RETISERT. RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg for intravitreal use Initial U.S. Approval: 19

Asclera [Merz North America, Inc]

These highlights do not include all the information needed to use Asclera Injection safely and effectively. See full prescribing information for Asclera. Asclera (polidocanol) Injection, for intravenous use Initial U.S. Approval: 2010

Indocyanine green [HUB Pharmaceuticals LLC]

Indocyanine Green for Injection USP

Ic-green [Akorn, Inc.]

These highlights do not include all the information needed to use IC-GREEN safely and effectively. See full prescribing information for IC-GREEN. IC-GREEN (indocyanine green for injection, USP) For Intravenous Injection Initial U.S. Approval: 1959

Triamterene and hydrochlorothiazide [Northwind Pharmaceuticals]

Triamterene and Hydrochlorothiazide 37.5 mg / 25 mg

Ranitidine [Aurobindo Pharma Limited]

Ranitidine Capsules Rx only

Ranitidine [Par Pharmaceutical Inc]

Ranitidine [McKesson Corporation]

Ranitidine [State of Florida DOH Central Pharmacy]

NA

Ranitidine [American Health Packaging]

Ranitidine Syrup (Ranitidine Oral Solution, USP) Rx Only 8426069/1218F

Ranitidine [PD-Rx Pharmaceuticals, Inc.]

Ranitidine Tablets, USP Rx Only



Advertisement
Quick Search
Advertisement
Advertisement